MidFirst Bank Makes New $612,000 Investment in West Pharmaceutical Services, Inc. $WST

MidFirst Bank acquired a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,225 shares of the medical instruments supplier’s stock, valued at approximately $612,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of WST. Elyxium Wealth LLC purchased a new position in shares of West Pharmaceutical Services during the fourth quarter worth about $25,000. Private Trust Co. NA raised its stake in West Pharmaceutical Services by 156.4% in the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 61 shares in the last quarter. DV Equities LLC bought a new stake in West Pharmaceutical Services during the fourth quarter valued at approximately $28,000. International Assets Investment Management LLC bought a new stake in West Pharmaceutical Services during the fourth quarter valued at approximately $31,000. Finally, CYBER HORNET ETFs LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter worth approximately $25,000. Institutional investors own 93.90% of the company’s stock.

Insider Activity

In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares of the company’s stock, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Chad Winters sold 896 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer directly owned 1,523 shares in the company, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by company insiders.

West Pharmaceutical Services Trading Up 0.2%

NYSE WST opened at $328.48 on Friday. The firm has a market cap of $23.21 billion, a PE ratio of 43.91, a price-to-earnings-growth ratio of 2.74 and a beta of 1.18. West Pharmaceutical Services, Inc. has a 1-year low of $206.80 and a 1-year high of $336.82. The stock has a 50-day moving average of $305.93 and a 200-day moving average of $273.41. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million during the quarter, compared to analysts’ expectations of $779.67 million. The firm’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.45 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. As a group, sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Stephens restated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Evercore reissued an “outperform” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, April 27th. Finally, Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $310.00 to $400.00 in a research note on Tuesday, June 9th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services has a consensus rating of “Buy” and a consensus target price of $340.09.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.